<DOC>
	<DOC>NCT00268996</DOC>
	<brief_summary>IBIS-2 is a study using SB-480848 versus placebo in subjects with angiographically documented coronary heart disease. Endpoints include coronary imaging, endothelial function, biomarkers, safety and tolerability.</brief_summary>
	<brief_title>Integrated Biomarker And Imaging Study - 2</brief_title>
	<detailed_description>Integrated Biomarker and Imaging Study -2 (IBIS-2): An International, Multicenter, Randomized, Placebo-controlled, Parallel-group, 1 Year Treatment, Integrated Biomarkers and Imaging Study in Subjects with Angiographically Documented Coronary Heart Disease (CHD) to Examine the Effects of the Novel Lipoprotein-associated Phospholipase A2 (Lp-PLA2) inhibitor SB-480848 on Intermediate Cardiovascular Endpoints, Patient Safety and Tolerability.</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Inclusion criteria: Successful PCI (Percutaneous Coronary Intervention) or uncomplicated diagnostic catheterization Suitable nonintervened coronary artery with IVUS Antiplatelet therapy Exclusion criteria: Clinical instability Previous CABG (Coronary Artery Bypass Graft) surgery Planned major surgery Recent stroke Abnormal QTc Renal or hepatic impairment Uncontrolled hypertension Use of corticosteroids Class III or IV heart failure Asthma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Lipoprotein-associated Phospholipase A2</keyword>
	<keyword>palpography</keyword>
	<keyword>hs-CRP</keyword>
	<keyword>Coronary artery disease</keyword>
	<keyword>endothelial function</keyword>
	<keyword>intravascular ultrasound</keyword>
</DOC>